Facility available :
 

 
The lab is well equipped with advanced diagnostic instruments such 2 ULTRA and 3 Ventana Benchmark XT automated Immunostainers, Histocore automated Microtome and FACS Lyrics 12 colour flow cytometer.

Clinical Services :

The lab works in co-ordination with Onco-pathology department by performing immunohistochemistry with two ULTRA and three Ventana Benchmark XT automated Immunostainers and leukemia/lymphoma immunophenotyping with FACS Lyrics 12 colour flow cytometer to aid histopathological diagnosis and haematological diagnosis, respectively.

Academic Activities :

The lab staff is involved in teaching of MSc Cancer Biology, PhD students and also in dissertation of DM Oncopathology students. The division enrols MSc dissertation students from other colleges, as well as MSc, MPharm, MDS and MD students as observers.

Research Activities :

The lab is involved in translational cancer research and seeks to accelerate the application of discoveries in the laboratory to clinical practice. It is based on identification of cellular and molecular changes that occur during pathogenesis of the cancer and during cancer progression which cause therapeutic resistance.

The current research focus on detection of Mismatch repair deficiency in endometrial and colon cancer by immunohistochemistry. In endometrial MMR status will be correlated with MSI status which could be done by NGS. Also a 19 gene panel by NGS would be evaluated in these patients to study the most specific mutations in our set of patients that would help in their treatment planning and possibly design a protein panel based on it. Further, PD-L1 expression studied by immunohistochemistry for their prognostic and therapeutic significance in different malignancy including TNBC, Lung cancer and Oral cancer. ALK-1 mutation is being evaluated in Lung Cancer.In endocrine resistant breast cancer CDK4/6, Cyclin D, ERα, PIK3CA is being evaluated to help find an alternative treatment line in patients who are resistant to endocrine therapy. Further, development of mutational signature by comprehensive genomic profiling in triple negative breast cancer .In addition, lab also evaluates minimal residual disease (MRD) detection by flow cytometry in Acute Leukemia.